Company news: Zelira; ECS Botanics; LGP; Ecofibre; Neurotech; Elixinol; Emyria by Steve Jones and Martin Lane February 28, 2024July 16, 2024 Zelira Therapeutics was hit with a A$30.7m impairment charge in the first half of the financial […]
Ecofibre sells hemp food and animal products business to Elixinol by Martin Lane February 12, 2024July 16, 2024
Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024
Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023
Ecofibre eyes commercial pathway after positive results from endometriosis studies by Martin Lane October 24, 2023April 30, 2024
Financial results: Bioxyne/BLS; Emyria; Ecofibre; Zelira Therapeutics by Martin Lane October 3, 2023April 30, 2024
Ecofibre shares soar 50% after firm strikes deal with Under Armour by Steve Jones July 31, 2023April 30, 2024
Ecofibre facing financial hit after hemp seed is damaged in transit by Steve Jones July 19, 2023April 30, 2024
